Call for withdrawal of LABA single-therapy inhaler in asthma

Lancet. 2010 Sep 4;376(9743):750-1. doi: 10.1016/S0140-6736(10)61158-0.
No abstract available

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / adverse effects
  • Adrenergic beta-Agonists / administration & dosage*
  • Adrenergic beta-Agonists / adverse effects
  • Albuterol / administration & dosage
  • Albuterol / analogs & derivatives
  • Androstadienes / administration & dosage
  • Anti-Asthmatic Agents / administration & dosage*
  • Anti-Asthmatic Agents / adverse effects
  • Asthma / drug therapy*
  • Asthma / mortality
  • Budesonide / administration & dosage
  • Budesonide / adverse effects
  • Budesonide, Formoterol Fumarate Drug Combination
  • Drug Combinations
  • Drug Recalls*
  • Drug Therapy, Combination
  • Ethanolamines / administration & dosage
  • Ethanolamines / adverse effects
  • Fluticasone
  • Formoterol Fumarate
  • Humans
  • Nebulizers and Vaporizers
  • Randomized Controlled Trials as Topic
  • Salmeterol Xinafoate
  • United States / epidemiology
  • United States Food and Drug Administration

Substances

  • Adrenal Cortex Hormones
  • Adrenergic beta-Agonists
  • Androstadienes
  • Anti-Asthmatic Agents
  • Budesonide, Formoterol Fumarate Drug Combination
  • Drug Combinations
  • Ethanolamines
  • Budesonide
  • Salmeterol Xinafoate
  • Fluticasone
  • Albuterol
  • Formoterol Fumarate